Development of novel therapy targeting microenvironment in respiratory malignancy

• Project Area: Integrative Research on Cancer Microenvironment Network
• Project/Area Number: 22112010
• Research Category: Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area)
• Allocation Type: Single-year Grants
• Review Section: Biological Sciences
• Research Institution: Kanazawa University
• Principal Investigator: YANO Seiji 金沢大学, がん進展制御研究所, 教授 (30294672)
• Co-Investigator(Kenkyū-buntansha): SUZUKI Takeshi 金沢大学, がん進展制御研究所, 教授 (30262075) ; NISHIOKA Yasuhiko 徳島大学, ヘルスバイオサイエンス研究部, 教授 (70274199) ; EBI Hiromichi 金沢大学, がん進展制御研究所, 助教 (00645145)
• Project Period (FY): 2010-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥86,060,000 (Direct Cost: ¥66,200,000、Indirect Cost: ¥19,860,000); Fiscal Year 2014: ¥15,470,000 (Direct Cost: ¥11,900,000、Indirect Cost: ¥3,570,000); Fiscal Year 2013: ¥16,250,000 (Direct Cost: ¥12,500,000、Indirect Cost: ¥3,750,000); Fiscal Year 2012: ¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000); Fiscal Year 2011: ¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000); Fiscal Year 2010: ¥20,670,000 (Direct Cost: ¥15,900,000、Indirect Cost: ¥4,770,000)
• Keywords: 微小環境 / 分子標的薬耐性 / EGFR変異肺がん / ALK肺がん / 中皮腫 / ALK阻害薬 / HGF / EGFRリガンド / 肺がん / 胸膜中皮腫 / EMT / 薬剤耐性 / 分子標的薬 / ヒストン脱メチル化酵素 / Met / 腫瘍 / 線維芽細胞 / 血管新生 / EGFR-TKI / ALK-TKI / FGFR1 / PDGFR / 腫瘍血管 / EGFR

Outline of Final Research Achievements

We found that microenvironment-derived growth factors, including HGF, induced resistance to tyrosine kinase inhibitors in EGFR mutant or ALK-fusion gene positive lung cancer. The resistance caused by microenvironment could be overcome by concomitant inhibition of growth factor receptors. In the orthotopic model of mesothelioma, we discovered that mesothelioma cells and fibroblasts formed the vicious cytokine network and promoted tumor progression, indicating that factors involved in this network would be ideal therapeutic targets for mesothelioma.

Research Products

• [Journal Article] Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations. (2015)
  • Author(s): Ebi H, Yano S, et al.
  • Journal Title: J Thorac Oncol Volume: 10 Issue: 1 Pages: 59-66
  • DOI: 10.1097/jto.0000000000000371
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Therapeutic activity of glycoengineered anti-GM2 antibody against malignant pleural mesothelioma. (2015)
  • Author(s): Li Q, Yano S, et al.
  • Journal Title: Cancer Sci Volume: 106 Issue: 1 Pages: 102-7
  • DOI: 10.1111/cas.12575
  • NAID: 120005666336
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. (2015)
  • Author(s): Nanjo S, Yano S, et al.
  • Journal Title: Cancer Sci Volume: 106 Issue: 3 Pages: 244-52
  • DOI: 10.1111/cas.12600
  • NAID: 120005830611
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] LPP inhibits collective cell migration during lung cancer dissemination. (2015)
  • Author(s): Tanaka M, Yano S, et al.
  • Journal Title: Oncogene Volume: in preｓs
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] TAS-115, a novel inhibitor of VEGFR-2 and Met, combined with erlotinib prevented re-growth of HGF-triggered erlotinib resistant lung cancer harboring EGFR mutation. (2014)
  • Author(s): Nakade J, Yano S, et al.
  • Journal Title: J Thorac Oncol Volume: 9 Issue: 6 Pages: 775-83
  • DOI: 10.1097/jto.0000000000000170
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. (2014)
  • Author(s): Tanimoto A, Yano S, et al.
  • Journal Title: Oncotarget Volume: 5 Pages: 4920-8
  • NAID: 120005830567
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer. (2014)
  • Author(s): Ohtsubo K, Yano S, et al.
  • Journal Title: Pancreas Volume: 43 Issue: 7 Pages: 1093-100
  • DOI: 10.1097/mpa.0000000000000168
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Distinct allelic expression patterns of imprinted IGF2 in adenocarcinoma and squamous cell carcinoma of the lung. (2014)
  • Author(s): Ozaki S, Yano S, et al.
  • Journal Title: Oncol Lett Volume: 8 Pages: 2561-4
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] The current state of molecularly targeted drugs targeting HGF/Met. (2014)
  • Author(s): Yano S, Nakagawa T.
  • Journal Title: Jpn J Clin Oncol Volume: 44 Issue: 1 Pages: 9-12
  • DOI: 10.1093/jjco/hyt188
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers. (2014)
  • Author(s): Ebi H, Yano S, et al.
  • Journal Title: Cancer Sci Volume: 105 Issue: 5 Pages: 499-505
  • DOI: 10.1111/cas.12383
  • NAID: 120005830600
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance. (2014)
  • Author(s): Takeuchi S, Yano S.
  • Journal Title: Respir Investig Volume: 52 Issue: 6 Pages: 348-56
  • DOI: 10.1016/j.resinv.2014.10.002
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. (2014)
  • Author(s): Moriya M, Yano S, et al.
  • Journal Title: Oncol Rep Volume: 31 Issue: 3 Pages: 1109-15
  • DOI: 10.3892/or.2013.2948
  • Peer Reviewed
• [Journal Article] Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. (2013)
  • Author(s): Nanjo S, Yano S, et al.
  • Journal Title: PLoS ONE Volume: 8 Issue: 12 Pages: e84700-e84700
  • DOI: 10.1371/journal.pone.0084700
  • NAID: 120005368227
  • Peer Reviewed
• [Journal Article] Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. (2013)
  • Author(s): Zhao L, Yano S, et al.
  • Journal Title: Cancer Sci Volume: 104 Issue: 12 Pages: 1640-6
  • DOI: 10.1111/cas.12301
  • NAID: 120005830610
  • Peer Reviewed
• [Journal Article] EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. (2013)
  • Author(s): Nakagawa T, Yano S, et al.
  • Journal Title: Cancer Res Volume: 73 Issue: 8 Pages: 2428-34
  • DOI: 10.1158/0008-5472.can-12-3479
  • Peer Reviewed
• [Journal Article] The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. (2013)
  • Author(s): Sano T, Yano S, et al.
  • Journal Title: Int J Cancer Volume: 133 Issue: 2 Pages: 505-13
  • DOI: 10.1002/ijc.28034
  • Peer Reviewed
• [Journal Article] mTOR inhibitors control erlotinib-resistance of EGFR mutant lung cancer cells triggered by HGF. (2013)
  • Author(s): Ishikawa D, Yano S, et al.
  • Journal Title: PLoS ONE Volume: 8 Issue: 5 Pages: e62104-e62104
  • DOI: 10.1371/journal.pone.0062104
  • Peer Reviewed
• [Journal Article] Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR activating and gatekeeper mutations. (2013)
  • Author(s): Yamada T, Yano S, et al.
  • Journal Title: Oncogene Volume: 32 Issue: 37 Pages: 4427-35
  • DOI: 10.1038/onc.2012.446
  • NAID: 120004997024
  • Peer Reviewed
• [Journal Article] Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. (2013)
  • Author(s): Ohtsubo K, Yano S, et al.
  • Journal Title: JOP Volume: 14 Pages: 515-20
  • DOI: 10.6092/1590-8577/1719
  • Peer Reviewed
• [Journal Article] Surfactant protein a suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages. (2013)
  • Author(s): Mitsuhashi A, Yano S, et al.
  • Journal Title: Am J Pathol Volume: 182 Issue: 5 Pages: 1843-53
  • DOI: 10.1016/j.ajpath.2013.01.030
  • Peer Reviewed
• [Journal Article] KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. (2013)
  • Author(s): Enkhbaatar Z, Yano S, et al.
  • Journal Title: Cell Cycle Volume: 12 Issue: 13 Pages: 2100-12
  • DOI: 10.4161/cc.25142
  • Peer Reviewed
• [Journal Article] PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. (2013)
  • Author(s): Ebi H, Yano S, et al.
  • Journal Title: PNAS Volume: 110 Issue: 52 Pages: 21124-9
  • DOI: 10.1073/pnas.1314124110
  • Peer Reviewed
• [Journal Article] EGFR-TKI resistance due to BIM polymorphism can be circumvented by in combination with HDAC inhibition. (2013)
  • Author(s): Nakagawa T, Yano S, et al.
  • Journal Title: Cancer Res Volume: 73(8) Pages: 2428-34
  • Peer Reviewed
• [Journal Article] Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. (2012)
  • Author(s): Wang W, Yano S, et al.
  • Journal Title: Clin Cancer Res Volume: 18(6) Pages: 1663-71
  • NAID: 120003830985
  • Peer Reviewed
• [Journal Article] Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. (2012)
  • Author(s): Yamada T, Yano S, et al.
  • Journal Title: Clin Cancer Res Volume: 18(13) Pages: 3592-602
  • Peer Reviewed
• [Journal Article] Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. (2012)
  • Author(s): Takeuchi S, Yano S, et al.
  • Journal Title: Am J Pathol Volume: 181(3) Pages: 1034-43
  • Peer Reviewed
• [Journal Article] Endoscopic findings of upper gastrointestinal lesions in patients withpancreatic cancer. (2012)
  • Author(s): Ohtsubo K, Yano S, et al.
  • Journal Title: JOP Volume: 13(4) Pages: 420-6
  • DOI: 10.6092/1590-8577/749
  • Peer Reviewed
• [Journal Article] Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR mutant lung cancer. (2012)
  • Author(s): Nakagawa T,Yano S, et al.
  • Journal Title: Mol Cancer Ther Volume: 11(10) Pages: 2149-57
  • Peer Reviewed
• [Journal Article] Hsp90 Inhibition Overcomes HGF Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis (2012)
  • Author(s): Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, and Yano S
  • Journal Title: Journal of Thoracic Oncology Volume: Vol. 7: no.7 Issue: 7 Pages: 1078-1085
  • DOI: 10.1097/jto.0b013e3182519a2c
  • Peer Reviewed
• [Journal Article] Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. (2012)
  • Author(s): Yamada T, Yano S, et al.
  • Journal Title: J Thorac Oncol Volume: 7(2) Pages: 272-80
  • Peer Reviewed
• [Journal Article] Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI. (2012)
  • Author(s): Uramoto H, Yano S, et al.
  • Journal Title: Anticancer Res Volume: 32(9) Pages: 3785-90
  • Peer Reviewed
• [Journal Article] Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma (2012)
  • Author(s): Kurai J, Chikumi HT, Hamada H, Yano S, , Hashimoto K, Takata M, Sako T, Yamaguchi K, Kinoshita N, Watanabe M, Touge H, Makino H, Igishi Shimizu E
  • Journal Title: International Journal of Oncology Volume: 41 Issue: 5 Pages: 1610-1618
  • DOI: 10.3892/ijo.2012.1607
  • Peer Reviewed
• [Journal Article] T790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKI (2012)
  • Author(s): Uramoto T, Yano S, Tanaka F
  • Journal Title: Lung Cancer Volume: 76 Issue: 1 Pages: 129-30
  • DOI: 10.1016/j.lungcan.2012.01.010
  • Peer Reviewed
• [Journal Article] Ligand-triggered resistance to molecular targeted drugs in lung cancer : roles of HGF and EGFR ligands (2012)
  • Author(s): Yano S, Takeuchi S, Nakagawa T, Yamada T
  • Journal Title: Cancer Sci Volume: (In press) Issue: 7 Pages: 1189-1194
  • DOI: 10.1111/j.1349-7006.2012.02279.x
  • Peer Reviewed
• [Journal Article] E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells (2012)
  • Author(s): Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Uenaka T, Yano S
  • Journal Title: Clin Cancer Res Volume: 18 Issue: 6 Pages: 1663-71
  • DOI: 10.1158/1078-0432.ccr-11-1171
  • Peer Reviewed
• [Journal Article] Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR mutant lung cancer by decreasing client protein expression and angiogenesis (2012)
  • Author(s): Koizumi H, Yano S, et al
  • Journal Title: J Thorac Oncol Volume: (In press)
  • Peer Reviewed
• [Journal Article] Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer (2012)
  • Author(s): Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S
  • Journal Title: J Thorac Oncol Volume: 7 Issue: 2 Pages: 272-80
  • DOI: 10.1097/jto.0b013e3182398e69
  • Peer Reviewed
• [Journal Article] Pleural mesothelioma instigates tumor associated fibroblasts to promote prog-ression via malignant cytokine network (2011)
  • Author(s): Li Q, Wang W, Yamada T, Matsumoto K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yano S.
  • Journal Title: Am J Pathol Volume: 179 Issue: 3 Pages: 1483-93
  • DOI: 10.1016/j.ajpath.2011.05.060
  • Peer Reviewed
• [Journal Article] Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort (2011)
  • Author(s): Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto U, Yasumoto Y, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M.
  • Journal Title: J Thorac Oncol Volume: 6 Issue: 12 Pages: 2011-7
  • DOI: 10.1097/jto.0b013e31823ab0dd
  • Peer Reviewed
• [Journal Article] Reaction of plasma hepatocyte growth factor level in lung cancer patients treated with EGFR-TKIs (2011)
  • Author(s): Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, Tachibana K, Noguchi M, Yano S, Hirata K.
  • Journal Title: Int J Cancer Volume: 126 Issue: 6 Pages: 1410-6
  • DOI: 10.1002/ijc.25799
  • Peer Reviewed
• [Journal Article] Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer (2011)
  • Author(s): Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S
  • Journal Title: Clin Cancer Res Volume: 17 Issue: 8 Pages: 2260-9
  • DOI: 10.1158/1078-0432.ccr-10-1993
  • Peer Reviewed
• [Journal Article] Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts (2011)
  • Author(s): Shiirevnyamba A, Yano S, et al
  • Journal Title: Br J Cancer Volume: 104 Pages: 505-513
  • Peer Reviewed
• [Journal Article] A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer (2011)
  • Author(s): Tomimoto H, Yano S, et al
  • Journal Title: Oncology Letter Volume: 2 Pages: 465-470
  • Peer Reviewed
• [Journal Article] The EGFR ligands amphiregulin and heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer (2011)
  • Author(s): Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, Takeuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S.
  • Journal Title: Clin Cancer Res Volume: 17 Issue: 11 Pages: 3619-30
  • DOI: 10.1158/1078-0432.ccr-10-2475
  • Peer Reviewed
• [Journal Article] E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor (2011)
  • Author(s): Ogino H, Hanibuchi M, Kakiuchi S, Trung Van The, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.
  • Journal Title: Mol Cancer Ther Volume: 10 Issue: 7 Pages: 1218-28
  • DOI: 10.1158/1535-7163.mct-10-0707
  • Peer Reviewed
• [Journal Article] Genetically engineered humanized anti-ganglioside GM2 anti-body against multiple organ metastasis produced by GM2 expressing small cell lung cancer (2011)
  • Author(s): Yamada T, Bando H, Takeuchi S, Kita K, Li Q, Wang W, Akinaga S, Nishioka Y, Sone S, Yano S.
  • Journal Title: Cancer Sci Volume: 102 Issue: 12 Pages: 2157-63
  • DOI: 10.1111/j.1349-7006.2011.02093.x
  • Peer Reviewed
• [Journal Article] Reaction of plasma hepatocyte growth factor level in lung cancer patients treated with EGFR-TKIs. (2011)
  • Author(s): Tanaka H, Yano S, et al.
  • Journal Title: Int J Cancer Volume: (In press)
  • Peer Reviewed
• [Journal Article] Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts. (2011)
  • Author(s): Shiirevnyamba A, Yano S, et al.
  • Journal Title: Br J Cancer Volume: 104 Pages: 505-513
  • Peer Reviewed
• [Journal Article] Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. (2011)
  • Author(s): Donev IS, Yano S, et al.
  • Journal Title: Clin Cancer Res Volume: 17 Pages: 2260-2269
  • Peer Reviewed
• [Journal Article] Epithelioid glioblastoma changed to typical glioblastoma-the methylation status of MGMT promoter and 5-ALA fluorescence-. (2011)
  • Author(s): Tanaka S, Yano S, et al.
  • Journal Title: Brain Tumor Pathol Volume: (In press)
  • Peer Reviewed
• [Journal Article] A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. (2011)
  • Author(s): Tomimoto H, Yano S, et al.
  • Journal Title: Oncology Letter Volume: (In press)
  • Peer Reviewed
• [Journal Article] The EGFR ligands amphiregulin and heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. (2011)
  • Author(s): Yasumoto K, Yano S, et al.
  • Journal Title: Clin Cancer Res Volume: (In press)
  • Peer Reviewed
• [Journal Article] Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. (2010)
  • Author(s): Yamada T, Yano S, et al.
  • Journal Title: Clin Cancer Res Volume: 16 Pages: 174-183
  • NAID: 120001939468
  • Peer Reviewed
• [Journal Article] Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice. (2010)
  • Author(s): Sakaguchi S, Yano S, et al.
  • Journal Title: Clin Exp Metastasis Volume: 27 Pages: 351-359
  • Peer Reviewed
• [Journal Article] Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage : a rare adverse effect of sunitinib. (2010)
  • Author(s): Yamada T, Yano S, et al.
  • Journal Title: Int J Clin Oncol Volume: 15 Pages: 638-641
  • NAID: 10027665563
  • Peer Reviewed
• [Journal Article] The role of percutaneous needle biopsy in differentiation of renal tumors. (2010)
  • Author(s): Izumi K, Yano S, et al.
  • Journal Title: Jpn J Clin Oncol Volume: 40 Pages: 1081-1086
  • Peer Reviewed
• [Journal Article] Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan. (2010)
  • Author(s): Kanematsu T, Yano S, et al.
  • Journal Title: J Med Invest Volume: 57 Pages: 326-333
  • NAID: 130004465225
  • Peer Reviewed
• [Presentation] Therapeutic activity of glycoengineered anti-GM2 antibody BIW-8962 against malignant pleural mesothelioma. (2015)
  • Author(s): Yano S.
  • Organizer: 15th Annual Targeted Therapies of The Treatment of Lung Cancer
  • Place of Presentation: Hotel Fairmont Miramar Wilshire Boulevard (USA)
  • Year and Date: 2015-02-19
  • Invited
• [Presentation] Bone microenvironment conferes Hsp90 inhibitor resistance in the metastatic small sell lung cancer. (2015)
  • Author(s): Yano S.
  • Organizer: Joint International Symposium on TGF-βFamily and Cancer
  • Place of Presentation: International Congress Center EPOCHAL TSUKUBA (Japan)
  • Year and Date: 2015-01-12
  • Invited
• [Presentation] Resistance to EGFR-TKI in EGFR mutant lung cancer. (2014)
  • Author(s): 矢野聖二
  • Organizer: 第73回日本癌学会学術総会
  • Place of Presentation: パシフィコ横浜
  • Year and Date: 2014-09-25
  • Invited
• [Presentation] 脳転移：腫瘍内科の視点から. (2014)
  • Author(s): 矢野聖二
  • Organizer: 第52回日本癌治療学会学術集会
  • Place of Presentation: パシフィコ横浜
  • Year and Date: 2014-08-28
  • Invited
• [Presentation] 肺がんの骨転移のメカニズムと分子標的治療. (2014)
  • Author(s): 矢野聖二
  • Organizer: 第23回日本がん転移学会学術集会・総会
  • Place of Presentation: 金沢市文化ホール
  • Year and Date: 2014-07-10
  • Invited
• [Presentation] 肺がんの分子標的治療薬耐性の機構解明と耐性克服治療開発. (2014)
  • Author(s): 矢野聖二
  • Organizer: 第18回日本がん分子標的治療学会学術集会
  • Place of Presentation: ホテルメトロポリタン仙台
  • Year and Date: 2014-06-25
  • Invited
• [Presentation] 日本における腫瘍内科教育の今後～分子標的薬体制の克服絵を目指した研究を通して～ (2014)
  • Author(s): 矢野聖二
  • Organizer: 第111回日本内科学会講演会
  • Place of Presentation: 東京国際フォーラム
  • Year and Date: 2014-04-11
  • Invited
• [Presentation] Strategy to Treat EGFR-TKI Resistance in EGFR Mutant Lung Cancer. (2012)
  • Author(s): Yano S.
  • Organizer: 5th Asia Pacific Lung Cancer Conference(APLCC)
  • Place of Presentation: Hilton Fukuoka Sea Hawk
  • Year and Date: 2012-11-26
  • Invited
• [Presentation] Ligand-stimulated receptor activation as novel targets to overcome resistance to molecular targeted drugs in lung cancer. (2012)
  • Author(s): 矢野聖二
  • Organizer: 第71回日本癌学会学術集会
  • Place of Presentation: ロイトン札幌
  • Year and Date: 2012-09-19
  • Invited
• [Presentation] Molecular mechanisms of EGFR－TKI resistance and strategy with HGF-Met inhibitors to overcome the resistance. (2012)
  • Author(s): 矢野聖二
  • Organizer: 第10回日本臨床腫瘍学会学術集会
  • Place of Presentation: 大阪国際会議場
  • Year and Date: 2012-07-26
  • Invited
• [Presentation] Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. (2012)
  • Author(s): Yano S.
  • Organizer: AACR Molecularly Targeted Therapies: Mechanisms of Resistance Conference
  • Place of Presentation: The Westin San Diego
  • Year and Date: 2012-05-09
• [Presentation] Receptor ligand-triggered resistance to molecular targeted drugs in lung cancer (2011)
  • Author(s): 矢野聖二
  • Organizer: 第52回日本肺癌学会総会
  • Place of Presentation: 大阪国際会議場(大阪府)
  • Year and Date: 2011-11-03
• [Presentation] がん転移のメカニズム (2011)
  • Author(s): 矢野聖二
  • Organizer: 第49回日本癌治療学会学術集会
  • Place of Presentation: 名古屋国際会議場(愛知県)
  • Year and Date: 2011-10-27
• [Presentation] EGFR ligands induce resistance to ALK inhibitors in EML4-ALK lung cancer cells (2011)
  • Author(s): 矢野聖二
  • Organizer: 第70回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場(愛知県)
  • Year and Date: 2011-10-03
• [Presentation] HGF-triggered EGFR-TKI resistance in EGFR mutant lung cancer (2011)
  • Author(s): 矢野聖二
  • Organizer: 第9回日本臨床腫瘍学会学術集会
  • Place of Presentation: パシフィコ横浜(神奈川県)
  • Year and Date: 2011-07-21
• [Presentation] HGFによるEGFR-TKI耐性の分子機構解明とその克服に向けた研究 (2010)
  • Author(s): 矢野聖二
  • Organizer: 第51回日本肺癌学会
  • Place of Presentation: 広島国際会議場(広島)(篠井・河合賞受賞講演 招待講演)
  • Year and Date: 2010-11-04
• [Presentation] マルチキナーゼ阻害薬を用いた胸膜中皮腫の薬物治療 (2010)
  • Author(s): 矢野聖二
  • Organizer: 第51回日本肺癌学会
  • Place of Presentation: 広島国際会議場(広島)
  • Year and Date: 2010-11-04
• [Presentation] EGFR遺伝子変異陽性肺がんにおけるEGFR-TKI耐性の克服 (2010)
  • Author(s): 矢野聖二
  • Organizer: 第48回日本癌治療学会
  • Place of Presentation: 国立京都国際会館(京都)
  • Year and Date: 2010-10-28
• [Presentation] EGFR肺がんのチロシンキナーゼ阻害薬耐性と治療戦略 (2010)
  • Author(s): 矢野聖二
  • Organizer: 第69回日本癌学会
  • Place of Presentation: 大阪国際会議場(大阪)
  • Year and Date: 2010-09-23
• [Presentation] 肺がんと骨転移 (2010)
  • Author(s): 矢野聖二
  • Organizer: 第28回日本骨代謝学会
  • Place of Presentation: 京王プラザホテル(東京)
  • Year and Date: 2010-07-22
• [Presentation] 分子標的薬剤の耐性機序及びその耐性克服を目指した臨床戦略.
  • Author(s): 矢野聖二
  • Organizer: 第22回日本がん転移学会学術集会・総会
  • Place of Presentation: ホテル ブエナビスタ
• [Presentation] Mechanisms of EGFR-TKI resistance and therapeutic strategies.
  • Author(s): 矢野聖二
  • Organizer: 第11回日本臨床腫瘍学会学術集会
  • Place of Presentation: 仙台国際センター
• [Presentation] Circumvention of molecular targeted drug-resistance in lung cancer.
  • Author(s): 矢野聖二
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: パシフィコ横浜
• [Presentation] Mechanisms of EGFR-TKI resistance and therapeutic strategies in lung cancer.
  • Author(s): 矢野聖二
  • Organizer: 第54回日本肺癌学会総会
  • Place of Presentation: ホテルニューオータニ
• [Presentation] Novel acquired resistance of molecular-targeted therapy for lung cancer.
  • Author(s): Yano S.
  • Organizer: American Thoracic Society 2013. (Meet the Professor)
  • Place of Presentation: Pennsylvania Convention Center,USA
• [Presentation] Resistance to EGFR TKIs.
  • Author(s): Yano S.
  • Organizer: IASLC 15th World Conference on Lung Cancer
  • Place of Presentation: Sydney Exhibition & Convention Centre, Australia
• [Remarks] 金沢大学附属病院がん高度先進治療センター 金沢大学がん進展制御研究所/腫瘍内科
  • URL: http://syuyounaika.w3.kanazawa-u.ac.jp/
• [Remarks] 金沢大学附属病院 がん高度先進治療センター 金沢大学がん進展制御研究所／腫瘍内科
  • URL: http://syuyounaika.w3.kanazawa-u.ac.jp/
• [Remarks] 金沢大学がん進展制御研究所腫瘍内科
  • URL: http://syuyounaika.w3.kanazawa-u.ac.jp
• [Remarks] 金沢大学がん進展制御研究所
  • URL: http://www.kanazawa-u.ac.jp/~ganken
• [Remarks]
  • URL: http://syuyounaika.w3.kanazawa-u.ac.jp/
• [Remarks]
  • URL: http://syuyounaika.w3.kanazawa-u.ac.jp/
• [Patent(Industrial Property Rights)] 肺癌患者の治療の有効性の予測検査方法及び肺癌治療剤のスクリーニング方法 (2013)
  • Inventor(s): 矢野聖二、竹内伸司、中川学之
  • Industrial Property Rights Holder: 矢野聖二、竹内伸司、中川学之
  • Industrial Property Rights Type: 特許
  • Filing Date: 2013-03-04